Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAMARIS VEGA

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1447351176
CMS profile
20048
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$33,260.11

294 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 4 of 6; records 151–200 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAMARIS VEGA

NPI 1447351176 · CMS profile ID 20048

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447351176?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAMARIS VEGA, NPI 1447351176, CMS profile ID 20048. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447351176?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DAMARIS VEGA, NPI 1447351176, CMS profile ID 20048. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447351176?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DAMARIS VEGA, NPI 1447351176, CMS profile ID 20048, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447351176?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

294 matching records · $33,260.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 294 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 294.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $9.6606/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811342095 CMS
AstraZeneca Pharmaceuticals LP $21.1606/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834347099 CMS
Insulet Corporation $7.0706/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839827879 CMS
DEXCOM, INC. $95.0206/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845302951 CMS
Amarin Pharma Inc. $17.0306/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815270469 CMS
PFIZER INC. $12.0806/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832512369 CMS
Novo Nordisk Inc $14.8006/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811342089 CMS
Xeris Pharmaceuticals, Inc. $24.3506/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837450053 CMS
Insulet Corporation $6.7206/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839827881 CMS
Novo Nordisk Inc $124.4006/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810813323 CMS
Novo Nordisk Inc $9.6206/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811000903 CMS
Novo Nordisk Inc $1,755.0006/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811342085 CMS
Novo Nordisk Inc $30.2406/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811632003 CMS
Clarus Therapeutics Inc. $11.2706/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855023579 CMS
Lilly USA, LLC $14.1306/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819030803 CMS
Abbott Laboratories $18.6506/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815533801 CMS
Novo Nordisk Inc $9.9806/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811718699 CMS
Insulet Corporation $6.7206/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839823415 CMS
Amgen Inc. $17.8606/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825237989 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.9806/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763325990 CMS
Novo Nordisk Inc $270.0006/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811631999 CMS
Novo Nordisk Inc $13.7106/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811718697 CMS
Insulet Corporation $7.3505/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839823417 CMS
AbbVie Inc. $12.7505/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796200757 CMS
Novo Nordisk Inc $110.0705/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811000889 CMS
Novo Nordisk Inc $1,755.0005/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811000897 CMS
Novo Nordisk Inc $2.2405/26/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811631997 CMS
Amgen Inc. $21.6605/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825237985 CMS
Novo Nordisk Inc $9.9005/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810813319 CMS
Insulet Corporation $8.7005/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839827883 CMS
Alexion Pharmaceuticals, Inc. $18.2905/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783122707 CMS
Novo Nordisk Inc $10.3305/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811486965 CMS
Novo Nordisk Inc $10.4605/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811000885 CMS
Novo Nordisk Inc $1.8905/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811631993 CMS
SANOFI-AVENTIS U.S. LLC $16.7405/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843564225 CMS
DEXCOM, INC. $14.4505/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845302949 CMS
Insulet Corporation $7.8905/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839823419 CMS
Novo Nordisk Inc $1,755.0005/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810674643 CMS
Novo Nordisk Inc $16.0005/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811000877 CMS
AbbVie Inc. $20.0005/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796200755 CMS
Novo Nordisk Inc $10.3905/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811342079 CMS
Insulet Corporation $7.7005/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839827885 CMS
Amneal Pharmaceuticals LLC $12.1605/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829683485 CMS
Clarus Therapeutics Inc. $14.0005/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855019985 CMS
Novo Nordisk Inc $10.2305/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811486961 CMS
Novo Nordisk Inc $10.6605/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811196971 CMS
Insulet Corporation $8.7304/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839823421 CMS
Amarin Pharma Inc. $16.7804/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815270463 CMS
Merck Sharp & Dohme Corporation $12.7504/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848512047 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.8004/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763325992 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $132,562.24 491
PY2020 $46,083.17 296
PY2021 $33,260.11 294
PY2022 $125,280.79 381
PY2023 $94,050.11 456
PY2024 $56,001.80 309
PY2025 $77,533.00 272

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $4,267,289.52 294
PY2024 Principal investigator $3,216,816.59 59
PY2023 Recipient $1,216.41 4
PY2023 Principal investigator $1,694,709.33 106
PY2022 Recipient $152,372.75 15
PY2022 Principal investigator $1,220,524.05 77
PY2021 Recipient $57,978.20 9
PY2021 Principal investigator $863,135.72 69
PY2020 Recipient $1,234.90 2
PY2020 Principal investigator $201,194.68 162
PY2019 Principal investigator $320,943.37 107

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

294 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202533763
Principal investigator 1 Amgen Inc. $8,333.00 12/24/2025 Non-covered Recipient Entity
JOHNSON COUNTY CLINTRIALS LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246643213
Principal investigator 1 Genentech, Inc. $34,790.00 12/19/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619430
Principal investigator 1 Genentech, Inc. $16,985.00 12/19/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211619433
Principal investigator 1 Hoffmann-La Roche Limited $17,200.00 12/19/2025 Non-covered Recipient Entity
JOHNSON COUNTY CLINTRIALS LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211619058
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 12/17/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673838
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 12/17/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673840
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 12/17/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673842
Principal investigator 1 Genentech, Inc. $3,333.00 12/11/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619425
Principal investigator 1 Genentech, Inc. $40,436.00 12/04/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619422
Principal investigator 1 Hoffmann-La Roche Limited $12,944.00 12/04/2025 Non-covered Recipient Entity
JOHNSON COUNTY CLINTRIALS LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211619055
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673654
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673656
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673828
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673830
Principal investigator 1 Genentech, Inc. $48,879.00 11/26/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211619413
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,513.90 11/24/2025 Non-covered Recipient Entity
Johnson County ClinTrials, LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220815199
Principal investigator 1 Ionis Pharmaceuticals, Inc. $9,124.00 11/24/2025 Non-covered Recipient Entity
JUNO RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246790604
Principal investigator 1 Ionis Pharmaceuticals, Inc. $525.00 11/24/2025 Non-covered Recipient Entity
JUNO RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246790608
Principal investigator 1 Genentech, Inc. $3,650.00 11/20/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619404
Principal investigator 1 Hoffmann-La Roche Limited $2,400.00 11/20/2025 Non-covered Recipient Entity
JOHNSON COUNTY CLINTRIALS LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211619043
Principal investigator 1 Hoffmann-La Roche Limited $59,379.00 11/20/2025 Non-covered Recipient Entity
JOHNSON COUNTY CLINTRIALS LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211619047
Principal investigator 1 Hoffmann-La Roche Limited $8,995.00 11/20/2025 Non-covered Recipient Entity
JOHNSON COUNTY CLINTRIALS LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211619051
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673664
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 11/19/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673666
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 11/19/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673668
Principal investigator 1 Boehringer Ingelheim International GmbH $12.42 11/19/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673670
Principal investigator 1 Genentech, Inc. $17,011.00 11/14/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619410
Principal investigator 1 Genentech, Inc. $13,702.00 11/14/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211619418
Principal investigator 1 Genentech, Inc. $16,958.00 11/07/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619395
Principal investigator 1 ABBVIE INC. $13,131.30 11/05/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521975
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673652
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673822
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673824
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673826
Principal investigator 1 Genentech, Inc. $10,945.00 10/29/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619369
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,200.00 10/29/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
IS354CS6 No dispute reported 06/30/2026 1246789784
Principal investigator 1 Genentech, Inc. $28,481.00 10/28/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211619384
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 10/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673658
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 10/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673660
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 10/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673662
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 10/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673832
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 10/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673834
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 10/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673836
Principal investigator 1 Genentech, Inc. $17,381.00 10/23/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619392
Principal investigator 1 Genentech, Inc. $22,083.00 10/16/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619365
Principal investigator 1 Hoffmann-La Roche Limited $83,808.00 10/16/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211619436
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,332.00 10/10/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797597
Principal investigator 1 ABBVIE INC. $6,078.80 10/09/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202515409
Principal investigator 1 Genentech, Inc. $40,177.00 10/09/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211619374
Principal investigator 1 Genentech, Inc. $13,683.00 10/09/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619388
Principal investigator 1 Ionis Pharmaceuticals, Inc. $450.00 10/08/2025 Non-covered Recipient Entity
JUNO RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246788329
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,000.00 10/08/2025 Non-covered Recipient Entity
JUNO RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246788334
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,000.00 10/08/2025 Non-covered Recipient Entity
JUNO RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246788339
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,060.00 10/08/2025 Non-covered Recipient Entity
JUNO RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246788344
Principal investigator 1 Ionis Pharmaceuticals, Inc. $15,027.50 10/08/2025 Non-covered Recipient Entity
JUNO RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246788347
Principal investigator 1 Genentech, Inc. $12,758.00 10/03/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619380
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673650
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673816
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673818
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673820
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673648
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673814
Principal investigator 1 Genentech, Inc. $15,907.00 09/23/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619296
Principal investigator 1 Genentech, Inc. $10,968.00 09/18/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211619323
Principal investigator 1 Genentech, Inc. $19,355.00 09/18/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619348
Principal investigator 1 Genentech, Inc. $15,814.00 09/12/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619360
Principal investigator 1 Genentech, Inc. $63,300.00 09/11/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211619287
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/10/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797623
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/10/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797625
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/10/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797627
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/10/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797629
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/10/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797631
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/10/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797633
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/10/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797635
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/10/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797637
Principal investigator 1 Eli Lilly and Company $111.45 09/09/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187885584
Principal investigator 1 ABBVIE INC. $9,094.80 09/04/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202508730
Principal investigator 1 Genentech, Inc. $21,620.00 09/04/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619318
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,248.00 09/03/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797599
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673632
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 09/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673786
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673788
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673790
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673812
Principal investigator 1 Genentech, Inc. $33,478.00 08/26/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619343
Principal investigator 1 Genentech, Inc. $5,484.00 08/21/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211619326
Principal investigator 1 Genentech, Inc. $5,318.00 08/21/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619330
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,630.00 08/20/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797621
Principal investigator 1 Genentech, Inc. $23,074.00 08/14/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619334
Principal investigator 1 Genentech, Inc. $33,378.00 08/14/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619357
Principal investigator 1 Genentech, Inc. $10,968.00 08/12/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211619314
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/08/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797585
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/08/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797587
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/08/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797589
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/08/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797591
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/08/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797593
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/08/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797595
Principal investigator 1 Genentech, Inc. $48,600.00 08/07/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211619353
Principal investigator 1 ABBVIE INC. $4,325.10 08/06/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503125
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673630
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673810
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,378.00 08/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797583
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 07/28/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673642
Principal investigator 1 Boehringer Ingelheim International GmbH $17.40 07/28/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673644
Principal investigator 1 Boehringer Ingelheim International GmbH $41.40 07/28/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673646
Principal investigator 1 Ionis Pharmaceuticals, Inc. $4,004.10 07/24/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
IS354CS6 No dispute reported 06/30/2026 1246785578
Principal investigator 1 Genentech, Inc. $30,334.00 07/22/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619338
Principal investigator 1 Genentech, Inc. $64,372.00 07/10/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211619283
Principal investigator 1 Genentech, Inc. $29,488.00 07/10/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619291
Principal investigator 1 Genentech, Inc. $31,908.00 07/10/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619300
Principal investigator 1 Genentech, Inc. $32,628.00 07/10/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619305
Principal investigator 1 Genentech, Inc. $19,033.00 07/10/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619310
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,376.50 07/09/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797617
Principal investigator 1 ABBVIE INC. $8,296.60 07/02/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494979
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673634
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673636
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673638
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673640
Principal investigator 1 Boehringer Ingelheim International GmbH $61.58 07/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673792
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673794
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673796
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673798
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673800
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673802
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673804
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673806
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673808
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,663.00 07/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797579
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,890.70 06/25/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797615
Principal investigator 1 F. Hoffmann-La Roche AG $490.00 06/24/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619245
Principal investigator 1 F. Hoffmann-La Roche AG $51,730.00 06/24/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619271
Principal investigator 1 F. Hoffmann-La Roche AG $8,995.00 06/19/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619242
Principal investigator 1 F. Hoffmann-La Roche AG $2,200.00 06/19/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619253
Principal investigator 1 F. Hoffmann-La Roche AG $19,640.00 06/19/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619256
Principal investigator 1 F. Hoffmann-La Roche AG $7,258.00 06/19/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619260
Principal investigator 1 F. Hoffmann-La Roche AG $2,400.00 06/19/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619275
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,360.00 06/12/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797577
Principal investigator 1 F. Hoffmann-La Roche AG $19,877.00 06/12/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619249
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 06/04/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797575
Principal investigator 1 ABBVIE INC. $20,079.80 06/03/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202487667
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673614
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673616
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673618
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673620
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673760
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673762
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673764
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673766
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673768
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673770
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673772
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673774
Principal investigator 1 Boehringer Ingelheim International GmbH $233.20 05/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673622
Principal investigator 1 Boehringer Ingelheim International GmbH $399.60 05/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673624
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 05/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673626
Principal investigator 1 Boehringer Ingelheim International GmbH $17.40 05/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673628
Principal investigator 1 Boehringer Ingelheim International GmbH $233.20 05/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673776
Principal investigator 1 Boehringer Ingelheim International GmbH $399.60 05/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673778
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 05/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673780
Principal investigator 1 Boehringer Ingelheim International GmbH $34.80 05/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673782
Principal investigator 1 Boehringer Ingelheim International GmbH $41.40 05/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673784
Principal investigator 1 F. Hoffmann-La Roche AG $17,226.00 05/27/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619264
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $130.00 05/12/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797581
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $130.00 05/12/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797619
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,500.00 05/09/2025 Non-covered Recipient Entity
JUNO RESEARCH
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185550906
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,119.20 05/09/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797611
Principal investigator 1 F. Hoffmann-La Roche AG $13,004.00 05/08/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619267
Principal investigator 1 ABBVIE INC. $15,319.20 05/07/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483745
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $341.08 05/07/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797613
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $262.74 05/06/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797573
Principal investigator 1 Eli Lilly and Company $46,480.00 05/05/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS ON A STABLE DOSE OF TIRZEPATIDE OR SEMAGLUTIDE WHO FAILED TO ACHIEVE HBA1C GOAL No dispute reported 06/30/2026 1187883950
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 05/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673604
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673606
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673608
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673610
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673612
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673744
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673746
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673748
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673750
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673752
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673754
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673756
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673758
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,463.00 05/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797571
Principal investigator 1 Eli Lilly and Company $107,745.00 04/28/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND LONG-TERM SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-2) No dispute reported 06/30/2026 1187885578
Principal investigator 1 F. Hoffmann-La Roche AG $12,317.00 04/28/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619279
Principal investigator 1 F. Hoffmann-La Roche AG $6,137.00 04/15/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619239
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,814.00 04/11/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797569
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,339.80 04/11/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797609
Principal investigator 1 ABBVIE INC. $3,069.30 04/03/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202473641
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673596
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673598
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673600
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673602
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673728
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673730
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673732
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673734
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673736
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673738
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673740
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673742
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,941.60 03/25/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797607
Principal investigator 1 F. Hoffmann-La Roche AG $6,203.00 03/25/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619227
Principal investigator 1 F. Hoffmann-La Roche AG $3,404.00 03/19/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619208
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,193.00 03/13/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797567
Principal investigator 1 F. Hoffmann-La Roche AG $1,973.00 03/11/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619205
Principal investigator 1 ABBVIE INC. $7,497.10 03/07/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202461108
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673580
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673582
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673584
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673586
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673702
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673704
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673706
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673708
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673710
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673712
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673714
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673716
Principal investigator 1 AstraZeneca Pharmaceuticals LP $218,228.00 02/28/2025 Non-covered Recipient Entity
JUNO RESEARCH
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1185550904
Principal investigator 1 Boehringer Ingelheim International GmbH $12.42 02/25/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673588
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 02/25/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673590
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 02/25/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673592
Principal investigator 1 Boehringer Ingelheim International GmbH $15.66 02/25/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673594
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 02/25/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673718
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 02/25/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673720
Principal investigator 1 Boehringer Ingelheim International GmbH $15.66 02/25/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673722
Principal investigator 1 Boehringer Ingelheim International GmbH $12.42 02/25/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673724
Principal investigator 1 F. Hoffmann-La Roche AG $3,463.00 02/25/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619223
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,326.00 02/20/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797565
Principal investigator 1 F. Hoffmann-La Roche AG $4,864.00 02/20/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619214
Principal investigator 1 F. Hoffmann-La Roche AG $3,000.00 02/20/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619219
Principal investigator 1 F. Hoffmann-La Roche AG $7,793.00 02/20/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619232
Principal investigator 1 F. Hoffmann-La Roche AG $3,250.00 02/20/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211619235
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $853.20 02/13/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797605
Principal investigator 1 ABBVIE INC. $8,409.70 02/06/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202448886
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673572
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673574
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673576
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673578
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673686
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673688
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673690
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673692
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673694
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673696
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673698
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673700
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,792.00 02/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797563
Principal investigator 1 Eli Lilly and Company $360.00 01/31/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1187883390
Principal investigator 1 Eli Lilly and Company $977.28 01/31/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187883946
Principal investigator 1 Eli Lilly and Company $1,901.66 01/31/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187885390
Principal investigator 1 Eli Lilly and Company $1,061.92 01/31/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187885804
Principal investigator 1 Amgen Inc. $89,025.71 01/30/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246643261
Principal investigator 1 Eli Lilly and Company $31,622.00 01/28/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1187885388
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,706.40 01/27/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797603
Principal investigator 1 Eli Lilly and Company $6,020.91 01/27/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187883388
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,740.00 01/22/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220797561
Principal investigator 1 Eli Lilly and Company $81.60 01/22/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187883948
Principal investigator 1 Eli Lilly and Company $90,679.00 01/21/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187883942
Principal investigator 1 Eli Lilly and Company $51,186.00 01/21/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187885386
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,560.60 01/17/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220797601
Principal investigator 1 Eli Lilly and Company $1,550.46 01/17/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY OF ONCE-WEEKLY TIRZEPATIDE PLUS MIBAVADEMAB COMPARED WITH TIRZEPATIDE ALONE IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1187883392
Principal investigator 1 Amgen Inc. $159,799.87 01/14/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246643274
Principal investigator 1 Eli Lilly and Company $2,221.63 01/13/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187885808
Principal investigator 1 Eli Lilly and Company $1,181.79 01/10/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187883940
Principal investigator 1 Eli Lilly and Company $6,754.24 01/09/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187886696
Principal investigator 1 Eli Lilly and Company $2,299.03 01/08/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187883382
Principal investigator 1 Eli Lilly and Company $390,914.00 01/07/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187883384
Principal investigator 1 Eli Lilly and Company $29,272.40 01/07/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187883386
Principal investigator 1 Eli Lilly and Company $262,285.00 01/07/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187883944
Principal investigator 1 Eli Lilly and Company $127,618.00 01/07/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187884148
Principal investigator 1 Eli Lilly and Company $53,765.00 01/07/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187884150
Principal investigator 1 Eli Lilly and Company $94,000.00 01/07/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187884152
Principal investigator 1 Eli Lilly and Company $174,577.16 01/07/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187885542
Principal investigator 1 Eli Lilly and Company $104,163.00 01/07/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY No dispute reported 06/30/2026 1187885802
Principal investigator 1 Eli Lilly and Company $659,286.00 01/07/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY OF ONCE-WEEKLY TIRZEPATIDE PLUS MIBAVADEMAB COMPARED WITH TIRZEPATIDE ALONE IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1187886692
Principal investigator 1 ABBVIE INC. $1,946.10 01/02/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202435283
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673564
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673566
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673568
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220673570
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673672
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673674
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673676
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673678
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673680
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673682
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673684
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Juno Research North Houston
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220673726
Principal investigator 1 Eli Lilly and Company $4,532.74 01/01/2025 Non-covered Recipient Entity
JUNO RESEARCH LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY No dispute reported 06/30/2026 1187885806